Rose McNulty

A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.

A recent study found that certain gene variants may be prognostic for residual disease following resection in patients with ovarian cancer.

An analysis of nationwide data over 2 decades identified demographic-specific trends in liver cancer incidence and mortality in the US.

A novel model for gauging nutritional risk among patients with hepatocellular carcinoma (HCC) showed high accuracy and may provide a simpler, more targeted alternative to currently used nutritional risk models used for patients with cancer.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop artificial pancreas systems can help reduce the burden of type 1 diabetes (T1D) management during pregnancy.

The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.

A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.

Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.

Leslie Busby, MD, chairman of the US Oncology Network Pharmacy & Therapeutics Committee, discusses the process of developing patient-centered care plans within the framework of an accountable care organization (ACO) and the importance of staying up to date with the latest best practices and therapies.

The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Patients with ovarian cancer living in rural areas reported less improvement in psychological function compared with patients living in urban areas in the year following ovarian cancer diagnosis.

Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.

Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.

Coverage in the February 2024 issue of Evidence-Based Oncology.

From the panel discussion, "The Burden They Carry," a discussion of the impact of financial toxicity over the duration of the cancer journey.

Experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology during Patient-Centered Oncology Care 2023.

The former NFL running back shared his story of overcoming cancer and encouraged an audience of oncologists, pharmacists, payers, and policy leaders to continue pushing to advance cancer treatment.

A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.

Coverage from the panel discussion, "Can Clinical Pathways Have Burnout, Too?" at Patient-Centered Oncology Care 2023.

Coverage from "Navigating the PBM Landscape: How a Heath Care Economist Sees It," at Patient-Centered Oncology Care 2023.

A review and meta-analysis found mirvetuximab soravtansine to have encouraging efficacy and a tolerable safety profile in patients with recurrent ovarian cancer with folate receptor alpha (FRα) expression.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop systems benefit patients managing type 1 diabetes.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.